Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PaSION

Financiado

Cerrado

A longitudinal assessment of treatment experience symptoms and potential associ...

A longitudinal assessment of treatment experience symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy Immuno-oncology (IO) and specifically immune checkpoint inhibitors (ICIs) have recently shown significant clinical benefit in a growing number of different tumor types. However 60-90% of the patients experience immune-related adve... ver más

31/08/2020

CHUV

175K€

Presupuesto del proyecto: 175K€

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-08-31

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CHUV

175.42K€ | Lider

Proyectos interesantes

IOO - Improving IO

Medical Technol...

Data Science

4M€ Cerrado

BioFlow

Medical Technol...

Data Science

150K€ Cerrado

CPP2021-008390

Medical Technol...

Cancer Research

225K€ Cerrado

cellsIMPACT

Medical Technol...

Data Science

178K€ Cerrado

ImmunoChip

Medical Technol...

Data Science

2M€ Cerrado

PID2020-119032RB-I00

Medical Technol...

Data Science

145K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2018-03-05
Fecha Fin: 2020-08-31

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 175K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immuno-oncology (IO) and specifically immune checkpoint inhibitors (ICIs) have recently shown significant clinical benefit in a growing number of different tumor types. However 60-90% of the patients experience immune-related adverse events (irAEs) associated with inflammatory or autoimmune responses that can affect any organ and system. Early recognition and treatment of these irAEs is crucial to reduce morbidity, organ complications and ultimately, mortality. Patient reported outcomes (PROs) result in earlier detection of symptom occurrence and severity compared to clinician reports, which tend to understate these experiences, and can serve as a reliable complementary indicator for AEs before their clinical manifestation. Although the use of PROs is highly recommended to be included as an endpoint in clinical trials, no IO-specific-PRO tool has been developed to date and the use of general cancer-specific instruments does not address the needs, concerns and specific symptoms experienced by patients undergoing ICI therapy. The overall objective of this project is therefore to gain a comprehensive understanding of patients’ experience over the immunotherapeutic treatment course based on qualitative interviews with patients, their caregivers and healthcare professionals. This will enable evaluating the need for adaptation or development of new IO-PRO measures. Furthermore, variations in immune-related biomarkers might predict the appearance and severity of symptoms and serve as surrogates for high-grade AEs risk stratification. Hence, this project will additionally investigate potential associations between symptoms and biomarkers over the treatment course in order to elucidate existing correlations. Results derived from this study will facilitate the development of more efficient and targeted care interventions based on the characteristics of the individual in the future, together advancing a patient-centered model of care in IO.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores